Inclusion Criteria:

1. Patients with histologically proven invasive breast cancer - the primary tumor size
is at least 5cm or cytologically proven axillary node metastasis

2. no evidence of systemic metastasis pathologically or radiologically

3. age at the time of diagnosis between 20 and 70 years

4. patients with previously untreated primary breast cancer including chemotherapy

5. general performance status with ECOG 0-2

6. sufficient hematopoietic function (absolute neutrophil count of ≥ 1,500/mm3, platelet
count of ≥ 100,000/mm3, and hemoglobin of ≥ 10 g/dL)

7. sufficient renal function (serum creatinine level of ≤ 1.5 mg/dL)

8. sufficient liver function (total serum bilirubin level ≤ 1.5 times the upper normal
limit; serum AST and ALT levels ≤ 1.5 times the upper normal limit; and serum
alkaline phosphatase level ≤ 1.5 times the upper normal limit)

9. sufficient cardiac function (normal electrocardiography within 1 month or LVEF>50% by
echocardiography or MUGA scan within 3 months)

10. patients who agree to enroll this clinical trial and sign the written informed
consent voluntarily

Exclusion Criteria:

1. patients with evidence of distant metastases

2. patients with other previous malignancy except breast cancer

3. pregnant (positive hCG test 1 week before registration) or lactating patient

4. uncontrolled serious infection

5. patients with psychiatric disease or epilepsy

6. patients with clinically severe cardiac disease within 6 months such as atrial or
ventricular arrhythmia, congestive heart failure, myocardial infarction, or unstable
angina

7. male breast cancer

8. patients with poor general condition who are not able to understand or sign the
written informed consent